23.46
price down icon36.06%   -13.24
after-market After Hours: 24.13 0.665 +2.83%
loading
Summit Therapeutics Inc stock is traded at $23.46, with a volume of 24.56M. It is down -36.06% in the last 24 hours and up +15.93% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$36.70
Open:
$34.48
24h Volume:
24.56M
Relative Volume:
7.16
Market Cap:
$18.60B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-97.77
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
-4.65%
1M Performance:
+15.93%
6M Performance:
+10.37%
1Y Performance:
+560.99%
1-Day Range:
Value
$22.22
$35.92
1-Week Range:
Value
$22.22
$36.91
52-Week Range:
Value
$2.10
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Name
Summit Therapeutics Inc
Name
Phone
305-203-2034
Name
Address
601 BRICKELL KEY DRIVE, MIAMI
Name
Employee
159
Name
Twitter
@summitplc
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
SMMT's Discussions on Twitter

Compare SMMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SMMT
Summit Therapeutics Inc
23.46 18.60B 956.00K -196.68M -113.02M -0.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-26-25 Upgrade Citigroup Neutral → Buy
Mar-21-25 Initiated Cantor Fitzgerald Overweight
Mar-12-25 Initiated Evercore ISI Outperform
Feb-28-25 Initiated Goldman Buy
Jan-08-25 Initiated Truist Buy
Dec-11-24 Initiated Wells Fargo Overweight
Dec-06-24 Initiated Jefferies Buy
Nov-04-24 Initiated JMP Securities Mkt Outperform
Sep-27-24 Downgrade Citigroup Buy → Neutral
Aug-12-24 Initiated H.C. Wainwright Buy
May-07-24 Initiated Citigroup Buy
Mar-26-24 Initiated Stifel Buy
Jun-28-18 Downgrade Janney Buy → Neutral
May-02-18 Initiated Janney Buy
Apr-12-18 Reiterated Needham Buy
Feb-13-18 Initiated BTIG Research Buy
Jan-04-18 Initiated SunTrust Buy
Dec-01-17 Resumed H.C. Wainwright Buy
Nov-16-16 Reiterated RBC Capital Mkts Outperform
Oct-05-16 Reiterated Needham Buy
Sep-16-16 Initiated H.C. Wainwright Buy
Mar-30-15 Initiated Needham Buy
Mar-30-15 Initiated Oppenheimer Outperform
View All

Summit Therapeutics Inc Stock (SMMT) Latest News

pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus

Apr 26, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize

Apr 25, 2025
pulisher
Apr 25, 2025

Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Sees Stock Drop Despite Positive Drug - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Gets Approval From China's Health Authority for Second Use of Ivonescimab - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial - Fierce Pharma

Apr 25, 2025
pulisher
Apr 25, 2025

Citi says buy Summit amid ‘significant market confusion’ - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Shares Resume Trading After Drug Appr - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics shares tumble following interim analysis By Investing.com - Investing.com Nigeria

Apr 25, 2025
pulisher
Apr 25, 2025

Merck gains after latest survival data for Summit’s cancer drug - MSN

Apr 25, 2025
pulisher
Apr 25, 2025

Merck stock gains on Summit data for cancer drug (MRK:NYSE) - Seeking Alpha

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics to resume trading at 3:20 pm ET - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

What's Going On With Summit Therapeutics Stock On Friday?Summit Therapeutics (NASDAQ:SMMT) - Benzinga

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Schedules Q1 2025 Earnings Call - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics shares tumble following interim analysis - Investing.com Australia

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT): Interim OS Analysis Requested from Chinese Health Authorities Shows Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive A - StreetInsider

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Stock Soars After Phase III Trial Suc - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Gains Attention Amid New Drug Approva - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’ - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Plummets After FDA Approval News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit plunges 35%; partner Akesso wins FDA nod for cancer drug - MSN

Apr 25, 2025
pulisher
Apr 25, 2025

Summit stock falls, partner Akesso wins FDA nod (SMMT:NASDAQ) - Seeking Alpha

Apr 25, 2025
pulisher
Apr 25, 2025

Jefferies uncovers China approval for Summit Therapeutics, ups target - TipRanks

Apr 25, 2025
pulisher
Apr 24, 2025

Summit Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) #2 - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 - Business Wire

Apr 24, 2025
pulisher
Apr 24, 2025

Summit Therapeutics (SMMT) Stock Rises on Positive Trial Data - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Summit Therapeutics gains on cancer trial data (SMMT:NASDAQ) - Seeking Alpha

Apr 24, 2025
pulisher
Apr 24, 2025

H.C. Wainwright maintains Buy on Summit Therapeutics stock By Investing.com - Investing.com Canada

Apr 24, 2025
pulisher
Apr 24, 2025

Summit Therapeutics stock soars to all-time high of $34.05 By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

Summit Therapeutics stock soars to all-time high of $34.05 - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Summit Therapeutics (SMMT) Surges on Positive Lung Cancer Treatm - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

H.C. Wainwright maintains Buy on Summit Therapeutics stock - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Mitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Amid Promising Ivonescimab Trial Results - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

Summit Therapeutics (SMMT) Surges on Positive Lung Cancer Treatment Results - GuruFocus

Apr 24, 2025
pulisher
Apr 23, 2025

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial By Stocktwits - Investing.com India

Apr 23, 2025

Summit Therapeutics Inc Stock (SMMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$32.20
price up icon 0.53%
$102.02
price down icon 15.36%
$69.69
price up icon 1.06%
biotechnology ONC
$244.90
price down icon 4.40%
$20.59
price up icon 0.24%
Cap:     |  Volume (24h):